EDRN is a leader in defining and using criteria for the validation of biomarkers—an essential condition for scientific progress. While myriad proteins and genes have been linked with a variety of cancers, acceptable biomarkers must be: reliable and repeatable in testing; highly sensitive and specific; quantitative; readily obtained by non-invasive methods; part of the causal pathway for disease; capable of being modulated by the che- mopreventive agent; and have high predictive value for clinical disease. EDRN is helping translate the discovery and validation of biomarkers to clinical use and we are delighted to be working toward that end. .
